Salma Omme, Samee Mohammed Abdul, Mustafa Muhammad Saqlain, Haseeb Abdul, Ho Wing Lam, Chan Hin Ming, Pons Andrea Gómez, Shafique Muhammad Ashir, Ali Syed Muhammad Sinaan, Raheem Abdul, Fadlalla Ahmad Tagwa Kalool
Osmania Medical College, Hyderabad, Telangana, India.
Jinnah Sindh Medical University, Karachi, Pakistan.
Ann Med Surg (Lond). 2025 Jan 9;87(1):265-275. doi: 10.1097/MS9.0000000000002742. eCollection 2025 Jan.
bloodstream infections pose a significant threat to public health and necessitate substantial healthcare resources. The optimal antimicrobial therapy for these infections remains a subject of debate. This systematic review and meta-analysis evaluated the efficacy and safety of early transition to oral antimicrobial therapy compared with continued intravenous (IV) therapy in patients with MRSA and MSSA bloodstream infections.
A PRISMA-guided systematic review and meta-analysis compared the early transition from intravenous to oral antibiotics with continued intravenous therapy in patients with infections, utilizing relevant studies from the PubMed, Embase, Scopus, and Web of Science databases from August 2003 to June 2024.
This meta-analysis of 11 studies (N = 54-220, primarily male, age: mid-30s to early 70s) revealed a 71.6% higher risk of all-cause mortality for patients transitioned to early oral therapy than for those who continued IV therapy (RR: 1.716; 95% CI: 1.039-2.836; = 0.035; I = 44%). Treatment failure, rehospitalization rates, adverse events, and hospital stay lengths did not differ significantly between groups.
Early oral antimicrobial therapy for bloodstream infections significantly reduces mortality compared to prolonged intravenous treatment, without increasing the incidence of adverse events or the risk of rehospitalization, suggesting its safety and efficacy as an alternative therapeutic approach; however, further randomized controlled trials are necessary to corroborate these findings.
血流感染对公众健康构成重大威胁,需要大量医疗资源。针对这些感染的最佳抗菌治疗方法仍是一个有争议的话题。本系统评价和荟萃分析评估了在耐甲氧西林金黄色葡萄球菌(MRSA)和甲氧西林敏感金黄色葡萄球菌(MSSA)血流感染患者中,与持续静脉注射(IV)治疗相比,早期过渡到口服抗菌治疗的疗效和安全性。
采用PRISMA指南进行系统评价和荟萃分析,比较了感染患者从静脉注射抗生素早期过渡到口服抗生素与持续静脉注射治疗的效果,利用了2003年8月至2024年6月期间来自PubMed、Embase、Scopus和Web of Science数据库的相关研究。
这项对11项研究(N = 54 - 220,主要为男性,年龄:35岁中期至70岁早期)的荟萃分析显示,与继续接受静脉注射治疗的患者相比,过渡到早期口服治疗的患者全因死亡率高71.6%(风险比:1.716;95%置信区间:1.039 - 2.836;P = 0.035;I² = 44%)。两组之间的治疗失败、再住院率、不良事件和住院时间没有显著差异。
与延长静脉注射治疗相比,早期口服抗菌治疗可显著降低血流感染的死亡率,且不增加不良事件发生率或再住院风险,表明其作为一种替代治疗方法的安全性和有效性;然而,需要进一步的随机对照试验来证实这些发现。